KOKOA
"Inā makemake mākou i kahi mea maopopo, lōʻihi ka manawa. Inā makemake mākou i kahi mea wikiwiki, pono mākou e ʻae e ʻike ʻia lākou he mau hōʻailona ʻino. ʻO ka ʻoiaʻiʻo, loaʻa kahi kano coronavirus, ʻoiaʻiʻo, ma mua o kekahi mau makahiki ʻaʻole wau i manaʻoʻiʻo. "
Ua ʻōlelo ʻo Dr. Pedro Cavadas i nā pilikia e pili ana i ka hoʻokele ʻana i nā lāʻau lapaʻau e kūʻē i ka coronavirus i ka manawa hoʻopaʻa i ka wā i hoʻopaʻa ʻole ʻia ai kahi maʻi ma ka honua holoʻokoʻa. ʻO ʻOkakopa 2020. E like me ka helu ʻana o ke kauka, ʻo ia kekahi o nā leo mua i ka hui ʻepekema Sepania e ʻōlelo aku i nā pilikia o ka covid, i mea e loaʻa ai kahi maʻi "palekana a maikaʻi" loa. pono e kali a hiki i ka hāʻule o kēia makahiki.
ʻO ka pono e hooki i ka maʻi maʻi coronavirus i alakaʻi i ka hoʻokomo ʻana i nā kano coronavirus ma mua o ka hoʻokumu ʻana o ka orthodoxy medical, e like me ka wehewehe ʻana o Pedro Cavadas, e hoʻokumu i ʻekolu mau ʻano like ʻole ma mua o kā lākou hoʻolaha.
ʻOiai aia ka manaʻo e pili ana i ka maikaʻi o nā lāʻau lapaʻau coronavirus ʻē aʻe e hoʻēmi i ka hopena o ka contagion, ʻo ka ʻoiaʻiʻo ʻo ia mai ka wā o ka inoculation o nā kau mua, ua hoʻonui ʻia nā hopena ʻino i ka poʻe i hoʻopunipuni i ke kauka Valencian.
Ua hoʻopaʻa ʻia ʻo Pedro Cavadas a ua hoʻomaka i kāna hoʻohewa ʻana i nā mea hōʻole coronavirus
Ma kēia mea, ua hōʻoia nā noiʻi hou e pili ana i nā hopena ʻaoʻao o nā kano coronavirus i ka thesis a Pedro Cavadas. ʻO kēia ka hihia o ka hōʻike i hoʻomākaukau ʻia e Kaohsiung Medical University ma Taiwan a paʻi ʻia e ka 'Journal of Clinical Medicine'.
ʻO ka noiʻi i hana ʻia e nā poʻe loea ʻĀsia i pili i nā kano Covid-19 me kahi hopena ʻaoʻao hou: ʻO OAB syndrome, ʻike ʻia hoʻi ʻo overactive bladder.
Hōʻike nā haʻawina i hana ʻia e ke kulanui ʻo Taiwanese i ka poʻe i hoʻopaʻa ʻia me ka nui o Pfizer, Astrazeneca a i ʻole Moderna e kūʻē i ka coronavirus e loaʻa i kekahi mau hopena maʻalahi. ʻO kēia mau mea e pili ana i ke kuni, ka maʻi maʻi, a me ka luaʻi.
I kēia hihia o ko mākou ʻāina, ua loaʻa i ka lawelawe pharmacovigilance o ka Spanish Agency for Medicines and Health Products (Aemps) he 70.965 mau hoʻolaha o nā hanana ʻino e pili ana i nā kano coronavirus a hiki i Mei i hala.
Nā hōʻike hou loa o WHO e pili ana i nā kano
Ma waho aʻe o ka ʻōlelo aʻo a Pedro Cavadas e pili ana i nā hopena e hiki ai i nā kano coronavirus ke kumu, ua ʻōlelo pū ke kauka Valencian e lawe ʻia nā maʻi e pili ana i ka covid "he mau makahiki" a hiki i ka lehulehu o ka honua. Ma kēia ʻano, ua hōʻoia nā hōʻike hou loa e ka World Health Organization (WHO) i kēia manaʻo.
No laila, e like me ka hopena o ka 75th World Health Assembly i mālama ʻia ma Geneva, ʻo 57 wale nō nā ʻāina i ka honua - ka hapa nui o ka loaʻa kālā kiʻekiʻe a kiʻekiʻe paha - ua hoʻopaʻa ʻia i kanahiku pakeneka o ko lākou poʻe noho. ʻO ka mea ʻē aʻe, e like me ka ʻōlelo a Pedro Cavadas, kokoke i kahi piliona kānaka ma nā ʻāina haʻahaʻa ʻaʻole i loaʻa i ka lāʻau lapaʻau.
Pono ka hihia o Kina i kahi ʻōlelo ʻokoʻa, kahi o ka nele o ka lāʻau lapaʻau no ka hui o ka poʻe ma mua o kanaono mau makahiki a me nā hemahema o kāna mau kano i alakaʻi ai i kona mana e hoʻoholo i nā mea e hoʻomanaʻo nei i nā mea i hoʻokō ʻia e ke Aupuni Sepania i 2022.
I kēia hihia, aia ka asymmetric evolution o ke kaʻina hana o ka lāʻau lapaʻau e paʻakikī i ka hoʻopau ʻana i ka coronavirus, wānana ʻo Dr. nā mea hōʻole i ka coronavirus.
ʻO kēia nā hopena ʻaoʻao nui o nā kano coronavirus
ʻO nā hopena ʻaoʻao e hōʻiliʻili i ka nui o nā leka hoʻomaopopo ma hope o ke kolu o ke kolu o ka maʻi Pfizer e kūʻē i ka coronavirus:
-Lymphadenopathy (nā ʻāʻī pehu) (30%)
-Pyrexia (fiber) (20%)
-He ʻeha poʻo (10%)
-Malgia (8%)
- ʻAʻohe pilikia (7%)
-Ka luhi (6%)
-Eha ma ka wahi hoʻomaha (4%)
-Ke anu (4%)
-Arthralgia (ʻeha hui) (3%)
-ʻEha Axillary (3%)
ʻO nā hopena ʻino loa i hōʻike ʻia ma hope o ka hoʻokō ʻana i ke kolu o ka hoʻopaʻa ʻana o ka lāʻau lapaʻau Moderna:
-Pyrexia (34%)
-He ʻeha poʻo (18%)
-Lymphadenopathy (16%)
-Malgia (12%)
- ʻAʻohe pilikia (9%
-Eha ma ka wahi hoʻomaha (9%)
-Nausea (8%)
-Ka luhi (8%)
-ʻAhaʻi (7%)
-Ke anu (6%)
